- Home
- KZIA vs ADIL Comparison
KZIA vs ADIL Comparison
Compare KZIA & ADIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZIA
- ADIL
- Stock Information
- Founded
- KZIA 1994
- ADIL 2010
- Country
- KZIA Australia
- ADIL United States
- Employees
- KZIA N/A
- ADIL N/A
- Industry
- KZIA Biotechnology: Pharmaceutical Preparations
- ADIL Biotechnology: Pharmaceutical Preparations
- Sector
- KZIA Health Care
- ADIL Health Care
- Exchange
- KZIA Nasdaq
- ADIL Nasdaq
- Market Cap
- KZIA 9.0M
- ADIL 7.7M
- IPO Year
- KZIA 1999
- ADIL 2018
- Fundamental
- Price
- KZIA $6.71
- ADIL $0.36
- Analyst Decision
- KZIA Strong Buy
- ADIL Strong Buy
- Analyst Count
- KZIA 3
- ADIL 2
- Target Price
- KZIA $16.00
- ADIL $4.75
- AVG Volume (30 Days)
- KZIA 188.3K
- ADIL 752.4K
- Earning Date
- KZIA 11-14-2025
- ADIL 11-12-2025
- Dividend Yield
- KZIA N/A
- ADIL N/A
- EPS Growth
- KZIA N/A
- ADIL N/A
- EPS
- KZIA N/A
- ADIL N/A
- Revenue
- KZIA $1,549,158.00
- ADIL N/A
- Revenue This Year
- KZIA N/A
- ADIL N/A
- Revenue Next Year
- KZIA $49.25
- ADIL N/A
- P/E Ratio
- KZIA N/A
- ADIL N/A
- Revenue Growth
- KZIA 248983.08
- ADIL N/A
- 52 Week Low
- KZIA $2.86
- ADIL $0.22
- 52 Week High
- KZIA $39.05
- ADIL $1.30
- Technical
- Relative Strength Index (RSI)
- KZIA 41.14
- ADIL 44.58
- Support Level
- KZIA $6.82
- ADIL $0.35
- Resistance Level
- KZIA $7.39
- ADIL $0.39
- Average True Range (ATR)
- KZIA 0.45
- ADIL 0.03
- MACD
- KZIA 0.02
- ADIL -0.00
- Stochastic Oscillator
- KZIA 28.33
- ADIL 19.22
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.